1. Scrip
  2. >>Therapy Areas
  3. >>Cardiovascular

Kitov Plans 2016 NDA For Arthritis Combo Drug

 
• By Mandy Jackson

Kitov Pharmaceuticals, which went public in the US in November, ended Dec. 15 with a 25.2% stock price gain at $4.47 per share based on positive Phase III results for lead drug candidate KIT-302 and the Israeli company's plans to seek US FDA approval for the treatment of osteoarthritis.

Kitov Pharmaceuticals, which went public in the US in November, ended Dec. 15 with a 25.2% stock price gain at $4.47 per share based on positive Phase III results for lead drug candidate KIT-302 and the Israeli company's plans to seek US FDA approval for the treatment of osteoarthritis.

KIT-302 combines Pfizer Inc.'s former blockbuster and now generic non-steroidal anti-inflammatory drug (NSAID) Celebrex (celecoxib) with the calcium channel blocker...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

Direct-To-Consumer And Lower Prices Key To Novo Nordisk’s Wegovy Fightback

 
• By Andrew McConaghie

The company’s incoming CEO Mike Doustdar has promised greater agility, competitiveness and execution, but investors are yet to be convinced.

Amvuttra Makes Strong ATTR-CM Showing As Alnylam Prepares For Global Launches

 
• By Alaric DeArment

In an interview, chief commercial officer Tolga Tanguler gave some ideas of what to expect as the company prepares to launch the drug for ATTR-CM in Europe.

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 
• By Andrew McConaghie

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.

Novartis Upbeat Even With Entresto Expiry Looming

 
• By Kevin Grogan

Swiss major confident that new oncology drugs will fill revenue gap.

More from Therapy Areas

Vedanta’s Live Bacteria Reach A Dead End In Ulcerative Colitis

 
• By Andrew McConaghie

The microbiome-based company’s trial of VE202 in ulcerative colitis has failed in Phase II, but its ongoing Phase III study in C difficile infection is more promising.

Post-GLP-1 Patients Are Significant Opportunity, But Response Sees More

 
• By Alaric DeArment

The company will move ahead in testing RDX-002 among overweight and obese patients coming off GLP-1s, but the CEO said antipsychotic-induced weight gain could represent a multibillion-dollar market.

PureTech’s New Spin-Off Wants Partners For Pulmonary Fibrosis Drug

 
• By Andrew McConaghie

Deupirfenidone hit its Phase II endpoint but the program remains risky and PureTech’s new Celea Therapeutics will aim to pull in extra funding for its late-stage development.